KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities: 2024-2025

Historic Total Non-Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Sep 2025 value amounting to $351.5 million.

  • Recursion Pharmaceuticals' Total Non-Current Liabilities rose 76.71% to $351.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $351.5 million, marking a year-over-year increase of 76.71%. This contributed to the annual value of $409.1 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Total Non-Current Liabilities stood at $351.5 million, which was down 7.89% from $381.6 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $409.1 million during Q4 2024, with a 5-year trough of $188.4 million in Q2 2024.
  • Over the past 2 years, Recursion Pharmaceuticals' median Total Non-Current Liabilities value was $359.0 million (recorded in 2025), while the average stood at $316.0 million.
  • Data for Recursion Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY skyrocketed of 102.56% (in 2025) over the last 5 years.
  • Recursion Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $409.1 million in 2024, then soared by 76.71% to $351.5 million in 2025.
  • Its Total Non-Current Liabilities was $351.5 million in Q3 2025, compared to $381.6 million in Q2 2025 and $366.5 million in Q1 2025.